Cancer cells originate from a series of acquired genetic mutations that can drive their
uncontrolled cell proliferation and immune evasion. Environmental factors, including the …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

The mutational landscape of colorectal cancer (CRC) does not enable predictions to be
made about the survival of patients or their response to therapy. Instead, studying the …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …

Although patients with microsatellite instable metastatic colorectal cancer (CRC) benefit from
immune checkpoint blockade, chemotherapy with targeted therapies remains the only …

The progression of cancer involves a critical step in which malignant cells escape from
control by the immune system. Antineoplastic agents are particularly efficient when they …